Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis

Aditi Sharma, Chakshu Sharma, Lalit Sharma, Pranay Wal, Preeti Mishra, Nitin Sachdeva, Shivam Yadav, Celia Vargas De-La Cruz, Sandeep Arora, Vetriselvan Subramaniyan, Ravi Rawat, Tapan Behl, Mukesh Nandave

Research output: Contribution to journalReview ArticleResearchpeer-review


Mostly, cardiovascular diseases are blamed for casualties in rheumatoid arthritis (RA) patients. Customarily, dyslipidemia is probably the most prevalent underlying cause of untimely demise in people suffering from RA as it hastens the expansion of atherosclerosis. The engagement of inflammatory cytokines like tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), etc., is crucial in the progression and proliferation of both RA and abnormal lipid parameters. Thus, lipid abnormalities should be monitored frequently in patients with both primary and advanced RA stages. An advanced lipid profile examination, i.e., direct role of apolipoproteins associated with various lipid molecules is a more dependable approach for better understanding of the disease and selecting suitable therapeutic targets. Therefore, studying their apolipoproteins is more relevant than assessing RA patients' altered lipid profile levels. Among the various apolipoprotein classes, Apo A1 and Apo B are primarily being focused. In addition, it also addresses how calculating Apo B:Apo A1 ratio can aid in analyzing the disease's risk. The marketed therapies available to control lipid abnormalities are associated with many other risk factors. Hence, directly targeting Apo A1 and Apo B would provide a better and safer option.

Original languageEnglish
Pages (from-to)305-317
Number of pages13
JournalCanadian Journal of Physiology and Pharmacology
Issue number5
Publication statusPublished - May 2024


  • apolipoproteins
  • cardiovascular disease
  • dyslipidemia
  • rheumatoid arthritis

Cite this